<?xml version='1.0' encoding='utf-8'?>
<document id="29627897"><sentence text="Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters."><entity charOffset="25-36" id="DDI-PubMed.29627897.s1.e0" text="cefiderocol" /><entity charOffset="52-65" id="DDI-PubMed.29627897.s1.e1" text="cephalosporin" /><pair ddi="false" e1="DDI-PubMed.29627897.s1.e0" e2="DDI-PubMed.29627897.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29627897.s1.e0" e2="DDI-PubMed.29627897.s1.e1" /></sentence><sentence text="Cefiderocol, a siderophore cephalosporin, will be used concomitantly with other medications for treatment of bacterial infections"><entity charOffset="0-11" id="DDI-PubMed.29627897.s2.e0" text="Cefiderocol" /><entity charOffset="27-40" id="DDI-PubMed.29627897.s2.e1" text="cephalosporin" /><pair ddi="false" e1="DDI-PubMed.29627897.s2.e0" e2="DDI-PubMed.29627897.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29627897.s2.e0" e2="DDI-PubMed.29627897.s2.e1" /></sentence><sentence text=" In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic cation transporter (OCT) 1, OCT2, multidrug and toxin extrusion (MATE) 2-K, and organic anion transporting polypeptide (OATP) 1B3"><entity charOffset="55-66" id="DDI-PubMed.29627897.s3.e0" text="cefiderocol" /></sentence><sentence text=" The aim of this study was to assess in vivo drug-drug interaction (DDI) potential of cefiderocol using probe substrates for these transporters"><entity charOffset="86-97" id="DDI-PubMed.29627897.s4.e0" text="cefiderocol" /></sentence><sentence text="" /><sentence text="DDI potentials of cefiderocol as inhibitors were assessed in a clinical study consisting of 3 cohorts"><entity charOffset="18-29" id="DDI-PubMed.29627897.s6.e0" text="cefiderocol" /></sentence><sentence text=" Twelve or 13 healthy adult subjects per cohort orally received a single dose of furosemide 20 mg (for OAT1/3), metformin 1000 mg (for OCT1/2 and MATE2-K), or rosuvastatin 10 mg (for OATP1B3) with or without co-administration with cefiderocol 2 g every 8 h with 3-h infusion (a total of 3, 6, and 9 doses of cefiderocol with furosemide, metformin, and rosuvastatin, respectively)"><entity charOffset="81-91" id="DDI-PubMed.29627897.s7.e0" text="furosemide" /><entity charOffset="112-121" id="DDI-PubMed.29627897.s7.e1" text="metformin" /><entity charOffset="159-171" id="DDI-PubMed.29627897.s7.e2" text="rosuvastatin" /><entity charOffset="183-190" id="DDI-PubMed.29627897.s7.e3" text="OATP1B3" /><entity charOffset="231-242" id="DDI-PubMed.29627897.s7.e4" text="cefiderocol" /><entity charOffset="308-319" id="DDI-PubMed.29627897.s7.e5" text="cefiderocol" /><entity charOffset="325-335" id="DDI-PubMed.29627897.s7.e6" text="furosemide" /><entity charOffset="337-346" id="DDI-PubMed.29627897.s7.e7" text="metformin" /><entity charOffset="352-364" id="DDI-PubMed.29627897.s7.e8" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e0" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e1" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e2" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e3" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e4" e2="DDI-PubMed.29627897.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e4" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e4" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e4" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e4" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e5" e2="DDI-PubMed.29627897.s7.e5" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e5" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e5" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e5" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e6" e2="DDI-PubMed.29627897.s7.e6" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e6" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e6" e2="DDI-PubMed.29627897.s7.e8" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e7" e2="DDI-PubMed.29627897.s7.e7" /><pair ddi="false" e1="DDI-PubMed.29627897.s7.e7" e2="DDI-PubMed.29627897.s7.e8" /></sentence><sentence text=" DDI potentials were assessed based on the pharmacokinetics of the substrates" /><sentence text="" /><sentence text="Ratios (90% confidence intervals) of maximum plasma concentration and area under the plasma concentration-time curve were 1" /><sentence text="00 (0" /><sentence text="71-1" /><sentence text="42) and 0" /><sentence text="92 (0" /><sentence text="73-1" /><sentence text="16) for furosemide, 1"><entity charOffset="8-18" id="DDI-PubMed.29627897.s16.e0" text="furosemide" /></sentence><sentence text="09 (0" /><sentence text="92-1" /><sentence text="28) and 1" /><sentence text="03 (0" /><sentence text="93-1" /><sentence text="15) for metformin, and 1"><entity charOffset="8-17" id="DDI-PubMed.29627897.s22.e0" text="metformin" /></sentence><sentence text="28 (1" /><sentence text="12-1" /><sentence text="46) and 1" /><sentence text="21 (1" /><sentence text="08-1" /><sentence text="35) for rosuvastatin, respectively"><entity charOffset="8-20" id="DDI-PubMed.29627897.s28.e0" text="rosuvastatin" /></sentence><sentence text=" Exposures to furosemide or metformin did not change when co-administered with cefiderocol"><entity charOffset="14-24" id="DDI-PubMed.29627897.s29.e0" text="furosemide" /><entity charOffset="28-37" id="DDI-PubMed.29627897.s29.e1" text="metformin" /><entity charOffset="79-90" id="DDI-PubMed.29627897.s29.e2" text="cefiderocol" /><pair ddi="false" e1="DDI-PubMed.29627897.s29.e0" e2="DDI-PubMed.29627897.s29.e0" /><pair ddi="false" e1="DDI-PubMed.29627897.s29.e0" e2="DDI-PubMed.29627897.s29.e1" /><pair ddi="false" e1="DDI-PubMed.29627897.s29.e0" e2="DDI-PubMed.29627897.s29.e2" /><pair ddi="false" e1="DDI-PubMed.29627897.s29.e1" e2="DDI-PubMed.29627897.s29.e1" /><pair ddi="false" e1="DDI-PubMed.29627897.s29.e1" e2="DDI-PubMed.29627897.s29.e2" /></sentence><sentence text=" Slight increase in rosuvastatin exposure was observed with co-administered with cefiderocol, which was not considered to be clinically significant"><entity charOffset="20-32" id="DDI-PubMed.29627897.s30.e0" text="rosuvastatin" /><entity charOffset="81-92" id="DDI-PubMed.29627897.s30.e1" text="cefiderocol" /><pair ddi="false" e1="DDI-PubMed.29627897.s30.e0" e2="DDI-PubMed.29627897.s30.e0" /><pair ddi="false" e1="DDI-PubMed.29627897.s30.e0" e2="DDI-PubMed.29627897.s30.e1" /></sentence><sentence text=" Each treatment was well tolerated" /><sentence text="" /><sentence text="Cefiderocol has no clinically significant DDI potential via drug transporters"><entity charOffset="0-11" id="DDI-PubMed.29627897.s33.e0" text="Cefiderocol" /></sentence><sentence text="" /></document>